scholarly journals Preliminary Study on the Formulation of Syariah Compliant Generic Sustained Release Gliclazide Tablet Using Xanthan Gum

2018 ◽  
Vol 17 (2) ◽  
Author(s):  
Nik Mohamad Lukman Mat Zin ◽  
Anis Syazwani Abd Mubin ◽  
Mohamed Sufian Mohd Nawi ◽  
Abul Bashar Mohammed Helaluddin ◽  
Abdul Razak Kasmur ◽  
...  
Keyword(s):  
Xanthan Gum ◽  
Insulin Dependent Diabetes Mellitus ◽  
Pharmaceutical Products ◽  
Dependent Diabetes Mellitus ◽  
Wet Granulation ◽  
British Pharmacopoeia ◽  
Sustain Release ◽  
Insulin Dependent ◽  
Preliminary Study ◽  
Muslim Patient

Gliclazide (1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea) is a second-generation sulfonylurea which is orally administered in the treatment of non-insulin-dependent diabetes mellitus in adults. Sustain release drugs help to improve drugs bioavailability by controlling the time of drug release or prolonging it. We are reporting the preliminary formulation of sustain release gliclazide tablets with careful choice of all the ingredients and processes related to syariah compliance manufacturing of pharmaceutical products. In this work, xanthan gum, a natural gum was used to achieve the sustain release criteria. The tablets were produced by wet granulation and semi-automatic tableting process. Tablet characterisation was done following the British Pharmacopoeia (BP) criteria. We expect that the outcome of our study will result in a suitable formulation that could be useful for the formulation of such product that will be helpful for the Muslim patient especially during the fasting month.

Elevated Circulating P-Selectin in Insulin Dependent Diabetes Mellitus

1996 ◽  
Vol 76 (03) ◽  
pp. 328-332 ◽  
Author(s):  
Bernd Jilma ◽  
Peter Fasching ◽  
Christine Ruthner ◽  
Anna Rumplmayr ◽  
Sabine Ruzicka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Insulin Dependent Diabetes Mellitus ◽  
Interquartile Range ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Intergroup Comparison ◽  
Median Plasma ◽  
Insulin Dependent

SummaryBased on findings that showed increased P-selectin expression on platelets and on choroidal microvessels of patients with insulin dependent diabetes mellitus (IDDM), we hypothesized that also plasma concentrations of circulating (c)P-selectin would be increased in these patients.The aim of this study was to compare the plasma levels of cP-selec-tin between non-smoking patients with IDDM, treated with an intensified insulin therapy, and healthy controls. The study design was prospective, cross-sectional and analyst-blinded. Subjects were matched individually for sex, age and body mass index. Plasma levels of cP-selectin and of von Willebrand antigen (vWF-Ag) were determined by enzyme linked immunoassays.Forty-two pairs were available for intergroup comparison. Median plasma concentrations of cP-selectin in patients with IDDM (285 ng/ml; interquartile range: 233-372) were on average 21% higher than those of controls (236 ng/ml; interquartile range: 175-296; p = 0.004). Also, median plasma levels of vWF-Ag were 10% higher in patients (96 U/dl; interquartile range: 82-127) than controls (87 U/dl; interquartile range: 70-104; p = 0.025). There was no correlation between plasma concentrations of cP-selectin and vWF-Ag levels in either group (p ώ0.05).In conclusion, our results of increased cP-selectin levels are in line with increased P-selectin expression on platelets and on choroidal microvessels found in patients with IDDM. In view of the currently developed small molecule inhibitors of cell adhesion molecules, these independent observations together may provide a sound rationale to select P-selectin as a target for treating or preventing IDDM-associated micro- or macrovascular complications.

Insulin release and pancreatic insulin is reduced in young prediabetic BB rats

1986 ◽  
Vol 112 (3) ◽  
pp. 367-371 ◽  
Author(s):  
Annette Svenningsen ◽  
Thomas Dyrberg ◽  
Helle Markholst ◽  
Christian Binder ◽  
Åke Lernmark
Keyword(s):  
Insulin Release ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Content ◽  
Dependent Diabetes Mellitus ◽  
Clinical Onset ◽  
Pancreatic Insulin ◽  
Pancreatic Insulin Content ◽  
Bb Rats ◽  
Insulin Dependent ◽  
The Mean

Abstract. The pancreases of approximately 50 days old diabetes-prone BB/Hagedorn (BB/H) and of the genetically closely related, but non-diabetic BB w-subline (control BB) rats were perfused to determine the capacity of D-glucose to release insulin before the expected development of diabetes. The BB/H rats were from a colony with 82–84% incidence of insulin-dependent diabetes mellitus (IDDM) by 140 days of age. The total amount of insulin released from the BB/H rat pancreas during stimulation with 20 mmol/l D-glucose was reduced by nearly 50% (P <0.01). The initial peak of insulin release was similar between the two groups of animals, whereas the amount of insulin released during the second peak accounted for the diminished release (P < 0.01). The extractable pancreatic insulin was 30% (P < 0.05) less in the BB/H rats. Total insulin release expressed relative to the pancreatic insulin content, was therefore not different between the two groups. It is concluded that about 20–40 days before the mean age of clinical onset of IDDM in BB/H rats, the capacity to release insulin in response to D-glucose is reduced along with a diminished pancreatic insulin content. This abnormality seems to be preceded only by islet cell surface antibodies but not by insulitis.

Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus

Diabetes ◽  
1986 ◽  
Vol 35 (2) ◽  
pp. 139-142 ◽  
Author(s):  
S. Srikanta ◽  
A. T. Ricker ◽  
D. K. McCulloch ◽  
J. S. Soeldner ◽  
G. S. Eisenbarth ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Beta Cell ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Beta Cell Dysfunction ◽  
Cell Dysfunction ◽  
Insulin Dependent
Sign in / Sign up

Export Citation Format

Share Document